Finn Edler von Eyben

Years Active: 2017-2024
Publications (10 Years): 6

Sankt Olavs Hospital Universitetssykehuset i Trondheim

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Sankt Olavs Hospital Universitetssykehuset i Trondheim Aug 01 2007 - Jan 26 2013

Norway

Consultant :: Medicine

Publications

Finn Edler von Eyben, Irene Virgolini, Richard Baum
Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer. Cancers 16 (14) (2024)
Finn Edler von Eyben, Kalevi Kairemo, Daniel S Kapp
Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review. Biomedicines 12 (4) (2024)
Finn Edler von Eyben, Kalevi Kairemo, Daniel S Kapp
Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review. Biomedicines 12 (4) (2024)
Finn Edler von Eyben, Irene Virgolini, Richard Baum
Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer. Cancers 16 (14) (2024)
Finn Edler von Eyben, Irene Virgolini, Richard Baum
Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer. Cancers 16 (14) (2024)
Finn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, Christian Uprimny, Irene Virgolini, Kalevi Kairemo, Timo Joensuu
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. European journal of nuclear medicine and molecular imaging 45 (3) (2017)

Finn Edler von Eyben.css-eqlu8i{font-size:small;padding-left:4px;}